晚期心衰:等待心脏移植与单纯持久机械循环支持的策略比较
该回顾性倾向匹配队列分析利用UNOS和INTERMACS注册数据(2010-2014年),比较晚期心衰患者接受左心室辅助装置(LVAD)Destination治疗与等待心脏移植(伴或不伴LVAD桥接)的5年生存。匹配后等待心脏移植策略与更好的5年生存相关(风险比0.42;95%CI 0.38-0.46),生存优势与心脏移植相关(调整风险比0.27;95%CI 0.24-0.32)。
要点
- 匹配后等待心脏移植策略5年生存优于LVAD Destination治疗(风险比0.42;95%CI 0.38-0.46)。
- 生存优势与心脏移植本身相关(调整风险比0.27;95%CI 0.24-0.32)。
- LVAD Destination治疗患者仍略年长(64.0岁 vs 60.0岁;P<.001),需前瞻性研究验证。
核心结论
- 在匹配若干相关临床因素后,心脏移植伴或不伴LVAD桥接治疗与优于LVAD Destination治疗的5年生存相关。
研究设计与样本
- 匹配的LVAD Destination治疗队列包含3411例患者;共8281例患者有白蛋白、肌酐和BMI数据并纳入分析。
主要发现
- 匹配后,LVAD Destination治疗患者(3411例)仍略年长于等待心脏移植患者(3411例)(64.0岁[IQR 55.0-70.0] vs 60.0岁[IQR 54.0-65.0];P<.001),性别无显著差异(2701例男性[79.2%] vs 2648例男性[77.6%];P=.13)。
- 等待心脏移植队列包括1607例LVAD桥接移植患者和1804例无LVAD患者。
- 匹配并调整关键临床因素后,等待心脏移植策略与更好的5年生存相关(风险比0.42;95%CI 0.38-0.46)。
- 生存优势与心脏移植相关(时间依赖移植状态的调整风险比0.27;95%CI 0.24-0.32)。
临床怎么用
- 对于晚期心衰患者,在匹配年龄、性别、BMI、肾功能和白蛋白水平后,等待心脏移植(伴或不伴LVAD桥接)可能提供更优的5年生存。
- LVAD Destination治疗可作为不适合移植患者的备选,但需与患者充分讨论生存差异。
局限性
- 回顾性研究设计,即使经过倾向匹配,LVAD Destination治疗患者仍略年长,可能存在残余混杂。
- 需要LVAD技术持续改进以及前瞻性比较研究来修正策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Given the shortage of donor hearts and improvement in outcomes with left ventricular assist device (LVAD) therapy, a relevant but, to date, unanswered question is whether select patients with advanced heart failure should receive LVAD destination therapy as an alternative to heart transplant. OBJECTIVE: To determine whether a strategy of LVAD destination therapy is associated with similar survival benefit as wait-listing for heart transplant with or without LVAD therapy among patients with advanced heart failure. DESIGN, SETTING, AND PARTICIPANTS: This retrospective propensity-matched cohort analysis used data on heart transplants from the United Network for Organ Sharing registry and LVAD implants from the Interagency Registry for Mechanically Assisted Circulatory Support from January 1, 2010, to December 31, 2014. The matched LVAD destination therapy cohort included 3411 patients. Data analysis for this study was conducted from December 22, 2017, to May 24, 2019. MAIN OUTCOMES AND MEASURES: Survival at 5 years was analyzed using Cox proportional hazards models. RESULTS: In total, 8281 patients had albumin level, creatinine level, and BMI data recorded and were included in the analysis. Despite propensity score matching, the 3411 patients receiving LVAD destination therapy still tended to be slightly older than the 3411 patients wait-listed for heart transplant (64.0 years [interquartile range, 55.0-70.0 years] vs 60.0 [interquartile range, 54.0-65.0 years]; P < .001), but there was no significant difference in sex (2701 men [79.2%] vs 2648 men [77.6%]; P = .13). After propensity score matching for age, sex, body mass index, renal function, and albumin level, 3411 patients were wait-listed for heart transplant. This included 1607 patients with bridge to transplant LVAD therapy and 1804 patients without LVAD. The strategy of wait-listing for heart transplant was associated with better 5-year survival than LVAD destination therapy (risk ratio, 0.42; 95% CI, 0.38-0.46) after matching and adjusting for key clinical factors. This survival advantage was associated with heart transplant (adjusted risk ratio for time-dependent transplant status, 0.27; 95% CI, 0.24-0.32). CONCLUSIONS AND RELEVANCE: The present analysis suggests that heart transplant with or without bridge to transplant LVAD therapy was associated with superior 5-year survival compared with LVAD destination therapy among patients matched on several relevant clinical factors. Continued improvement in LVAD technology, along with prospective comparative research, appears to be needed to amend this strategy.
引用
- Lala A, Rowland JC, Ferket BS, et al. Strategies of Wait-listing for Heart Transplant vs Durable Mechanical Circulatory Support Alone for Patients With Advanced Heart Failure. JAMA Cardiol. 2020. PMID: 32293643. doi:10.1001/jamacardio.2020.0631
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。